Basal insulin combined with acarbose compared with premixed insulin treatment of type 2 diabetes efficacy and safety
10.3969/j.issn.1005-1678.2017.09.012
- VernacularTitle:基础胰岛素联合阿卡波糖对比预混胰岛素治疗2型糖尿病疗效和安全性
- Author:
Donghong TAO
;
Xiao LIU
- Keywords:
insulin;
acarbose;
premixed insulin therapy;
type 2 diabetes;
treatment effect
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):38-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the analysis of insulin glargine combined with acarbose in type 2 diabetes compared with pre mixed insulin treatment efficacy and safety. Methods 100 patients with type 2 diabetes mellitus treated in our hospital from March 2015 to August 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group were treated with premixed insulin treatment, the experimental group were treated with basal insulin combined with acarbose. The clinical indexes of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, the fasting blood glucose level of the control group was (7.56 ± 1.13) nmol / L, and the fasting blood glucose level of the experimental group was (7.01 ± 0.92) nmol / L. The level of fasting blood glucose in the experimental group was significantly lower than that in the control group, with statistical difference (P<0.05). The level of HbA1c in the experimental group was (7.01 ± 0.82)％, significantly lower than that in the control group, and the level of HbA1c (7.45 ± 0.91)％, with statistical difference (P<0.05). Among the 50 patients in the control group, hypoglycemia occurred in 20 patients, the incidence of hypoglycemia was 40％, significantly higher than that in the experimental group, and the incidence of hypoglycemia was 14％, which was statistically significant (P<0.05). Conclusion Basal insulin combined with acarbose compared with premixed insulin treatment of type 2 diabetes treatment can significantly hypoglycemic effect, high safety, with further clinical promotion and application significance.
